Frontlight ResearchEarly access
CompletedNo phase
Apneic Oxygenation by Transnasal Humidified Rapid Insufflation Ventilator Exchange Obstructive Sleep Apnea Patients
Key facts
- Who runs it
- Beijing Tongren Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 56 people enrolled
- Started
- 1 Sept 2024
- Ended
- 13 Apr 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- THRIVE
- THRIVE combine nasopharyngeal airway
- Record updated
- 17 April 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- patients aged between 18 and 75 years requiring general anesthesia
- American society of Anesthesiologists (ASA) physical status classification system: I - III
- diagnosed as OSA
Who cannot take part
- patients with previous or anticipated difficult facemask ventilation or intubation,
- Patients with chronic respiratory disease, uncontrolled hypertension, ischemic heart disease, congestive heart failure, increased intracranial pressure, gastroesophageal reflux disease,
- patients with known allergy or contraindication to propofol, remifentanil, rocuronium, or midazolam
- patients' arterial hemoglobin saturation < 98% after preoxygenation,
- patients were nasal obstruction
- patients who were unable to give informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of the study is to compare effectiveness of different methods of achieving oxygenation in obstructive sleep apnea patients. The investigators intend to compare transnasal humidified rapid-insufflation ventilator exchange (THRIVE) combined with nasopharyngeal airway with THRIVE alone.
The 2 groups in the trial
- oxygenation using THRIVE techniqueExisting treatment, for comparison
oxygenation delivered via nasal high flow humidified oxygen (Optiflow) . 70 litres/minute
Treatment: THRIVE
- THRIVE combined nasopharyngeal airwayTreatment being tested
oxygenation delivered via nasopharyngeal airway and THRIVE technique. 70 litres/minute
Treatment: THRIVE combine nasopharyngeal airway
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Apnoeic Oxygenation in Obstructive Sleep Apnea: a Randomised Controlled Trial Comparing Transnasal Humidified Rapid Insufflation Ventilator Exchange (THRIVE) Combined With Nasopharyngeal Airway and THRIVE Alone
- Publications
- Record updated
- 17 April 2025